Predictive Oncology director awarded 64,680 RSUs; 85,882 shares owned after grant

Rhea-AI Filing Summary

Predictive Oncology Inc. director Gregory St. Clair Sr. was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share upon vesting and the grant carries a $0.00 purchase price. The RSUs vest in full on October 31, 2025, subject to continued service through that date. After the grant, the reporting person is shown as beneficially owning 85,882 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.

Positive

• Director received equity compensation via 64,680 RSUs, creating alignment with shareholders if vested
• Vesting date is specified (October 31, 2025), providing clear timeline for when shares may be issued

Negative

• RSU grant may increase potential shares outstanding upon vesting (post‑transaction beneficial ownership reported as 85,882)

Insights

Financial Analyst

TL;DR Director received a time‑based RSU grant of 64,680 shares vesting October 31, 2025.

The grant is a non‑cash equity award recorded at a $0.00 transaction price on Form 4, indicating issuance of restricted stock units rather than a market purchase. The size of the grant relative to the reported post‑transaction beneficial ownership of 85,882 shares suggests a material incremental equity position for the reporting person. This is a routine compensation/retention action rather than a market transaction and has a clear vesting date tied to continued service.

Corporate Governance Expert

TL;DR Time‑based RSUs were granted to a director and vest upon continued service on a specified future date.

The disclosure identifies the award as restricted stock units that vest in full on October 31, 2025, conditioned on continued service. The filing was made by one reporting person and executed by an attorney‑in‑fact, consistent with standard insider reporting practices. The Form 4 provides clear record of timing and ownership following the grant, enabling transparency around insider compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ST. CLAIR GREGORY SR

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A		64,680(1)	A	$0.00	85,882	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on October 31, 2025, subject to continued service through the applicable vesting date.

	/s/ Josh Blacher, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did POAI director Gregory St. Clair Sr. receive on 09/09/2025?

He was granted 64,680 restricted stock units (RSUs) on 09/09/2025 as reported on the Form 4.

When do the RSUs granted to the POAI director vest?

The RSUs vest in full on October 31, 2025,subject to continued service through that date.

How many shares does the reporting person beneficially own after the transaction?

Following the reported transaction the reporting person beneficially owns 85,882 shares.

What price was reported for the RSU grant on the Form 4?

The transaction price reported for the RSU grant is $0.00.

Who filed or signed the Form 4 on behalf of the reporting person?

The Form 4 was signed by an attorney‑in‑fact on 09/11/2025.